Key facts
- A-SEEDS’s last known valuation is $21.5M (Jul 2025).
- It has raised $19.5M; the latest was Later Stage VC ($16.4M) in Jul 2025.
- Notable investors include SMBC Venture Capital, Mizuho Capital, Nippon Venture Capital, Delight Ventures, Osaka University Venture Capital — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for A-SEEDS
- ·The full record, as it builds
Funding rounds
No funding rounds for A-SEEDS are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About A-SEEDS
Operator of a medical research company intended to focus on the realization and commercialization of CAR-T therapy. The company aims to commercialize gene therapy using GMR-CAR and focus on the research and development of new CAR-T therapies, supply of raw materials to popularize CAR-T therapy, as well as implement technical guidance on cell culture, enabling the medical community to have assistance in the practical application of CAR-T therapy.
- Sector
- Healthcare
- HQ
- Matsumoto, Japan
- Founded
- 2020
- Employees
- 2
- Website
- a-seeds.co.jp/
- Ownership
- Privately Held (backing)
A-SEEDS doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in A-SEEDS shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on A-SEEDS in its N-PORT filings yet. We sweep new filings monthly.